Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.

"all source codes have been archived at 10 5281/zenodo 6844694 and are publicly accessible from the date of publication."

"all source codes have been archived at 10 5281/zenodo 6844694 and are publicly accessible from the date of publication."

"Declarations Ethics approval and consent to participateAll animal experiments conducted in this study were carried out in accordance with the guidelines and regulations set forth by the Institutional Animal Care and Use Committee of Korea University, with approval numbers KUIACUC-2019-0101 and KUIACUC-2022-0049. Competing interestsJSK and KML are named inventors on a patent for a pharmaceutical composition to prevent or treat cancer-comprising monocytes or macrophages that inhibit CD244 expression or activity as an active ingredient (KR10-2022-0067313, PCT/KR2023/007574). Competing interests JSK and KML are named inventors on a patent for a pharmaceutical composition to prevent or treat cancer-comprising monocytes or macrophages that inhibit CD244 expression or activity as an active ingredient (KR10-2022-0067313, PCT/KR2023/007574)."

"Funding KML was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (RS-2023-00225581, RS-2023-00219002, NRF-2020R1A2C2103061) and Korea Health Industry Development Institute funded by Ministry of Health and Welfare (HD22C2045)."